Insights

Innovative Platform Silence Therapeutics’ proprietary mRNAi GOLD™ platform positions the company as a leader in developing cutting-edge siRNA therapies, offering potential collaborative opportunities to pharmaceutical firms seeking advanced genetic medicine solutions.

Expanding Clinical Pipeline With positive topline data from multiple Phase 2 trials for indications such as high Lipoprotein(a) and polycythemia vera, Silence demonstrates a robust clinical pipeline that may open doors for partners interested in early-to-late stage RNA-based therapies.

Strategic Collaborations Recent partnerships, including with the Global MPN Scientific Foundation, showcase Silence’s commitment to advancing treatments for rare diseases, creating avenues for joint development and co-marketing agreements with organizations focused on niche markets.

Market Growth Potential Silence’s focus on genetically driven conditions aligns with broader market trends toward personalized medicine, presenting opportunities to engage with healthcare companies targeting underserved patient populations through innovative genetic therapies.

Financial Strength With substantial funding of around $120 million and a revenue range of $25 to $50 million, Silence offers a financially stable platform for strategic partnerships, investment, and co-development deals in the growing RNA therapeutics space.

Silence Therapeutics plc Tech Stack

Silence Therapeutics plc uses 8 technology products and services including Veeam, WordPress, Microsoft Excel, and more. Explore Silence Therapeutics plc's tech stack below.

  • Veeam
    Backup And Recovery
  • WordPress
    Content Management System
  • Microsoft Excel
    Editors
  • Microsoft 365
    Email
  • SAP S/4HANA
    Enterprise Resource Planning
  • Yoast SEO
    Search Engines
  • VMware
    Virtualisation Software
  • Q4 Cookie Monster
    Widgets

Media & News

Silence Therapeutics plc's Email Address Formats

Silence Therapeutics plc uses at least 1 format(s):
Silence Therapeutics plc Email FormatsExamplePercentage
F.Last@silence-therapeutics.comJ.Doe@silence-therapeutics.com
83%
FLast@silence-therapeutics.comJDoe@silence-therapeutics.com
13%
Last@silence-therapeutics.comDoe@silence-therapeutics.com
3%
First@silence-therapeutics.comJohn@silence-therapeutics.com
1%

Frequently Asked Questions

Where is Silence Therapeutics plc's headquarters located?

Minus sign iconPlus sign icon
Silence Therapeutics plc's main headquarters is located at 72 Hammersmith Road London, England w14 8th United Kingdom. The company has employees across 2 continents, including EuropeNorth America.

What is Silence Therapeutics plc's phone number?

Minus sign iconPlus sign icon
You can contact Silence Therapeutics plc's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Silence Therapeutics plc's stock symbol?

Minus sign iconPlus sign icon
Silence Therapeutics plc is a publicly traded company; the company's stock symbol is SLN.

What is Silence Therapeutics plc's official website and social media links?

Minus sign iconPlus sign icon
Silence Therapeutics plc's official website is silence-therapeutics.com and has social profiles on LinkedInCrunchbase.

What is Silence Therapeutics plc's SIC code NAICS code?

Minus sign iconPlus sign icon
Silence Therapeutics plc's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Silence Therapeutics plc have currently?

Minus sign iconPlus sign icon
As of May 2026, Silence Therapeutics plc has approximately 90 employees across 2 continents, including EuropeNorth America. Key team members include Cso: K. G.Chief Scientific Officer: M. W. L.Chief Medical Officer, Svp: C. R.. Explore Silence Therapeutics plc's employee directory with LeadIQ.

What industry does Silence Therapeutics plc belong to?

Minus sign iconPlus sign icon
Silence Therapeutics plc operates in the Biotechnology Research industry.

What technology does Silence Therapeutics plc use?

Minus sign iconPlus sign icon
Silence Therapeutics plc's tech stack includes VeeamWordPressMicrosoft ExcelMicrosoft 365SAP S/4HANAYoast SEOVMwareQ4 Cookie Monster.

What is Silence Therapeutics plc's email format?

Minus sign iconPlus sign icon
Silence Therapeutics plc's email format typically follows the pattern of F.Last@silence-therapeutics.com. Find more Silence Therapeutics plc email formats with LeadIQ.

How much funding has Silence Therapeutics plc raised to date?

Minus sign iconPlus sign icon
As of May 2026, Silence Therapeutics plc has raised $120M in funding. The last funding round occurred on Feb 05, 2024 for $120M.

When was Silence Therapeutics plc founded?

Minus sign iconPlus sign icon
Silence Therapeutics plc was founded in 1999.

Silence Therapeutics plc

Biotechnology ResearchEngland, United Kingdom51-200 Employees

Our 20-plus years of RNAi experience together with our validated mRNAi GOLD™ platform make us a 
partner of choice for pharmaceutical companies looking to access the benefits of the siRNA and add 
this revolutionary modality to their discovery pipeline. As pioneers in the design and development of 
siRNAs (short interfering RNAs), Silence Therapeutics is advancing a new generation of medicines to 
potentially address the needs of patients who have limited or inadequate treatment options.
Our mission is to use our technology to create a new generation of therapeutics which can improve 
outcomes for patients and, in the process, build shareholder value.
We are developing a deep pipeline of innovative siRNAs based on our mRNAi GOLD™ platform for 
diseases with a genetic basis. The depth and versatility of our liver-targeting technology gives us the 
opportunity to address a wide range of conditions in virtually any therapeutic area. 

Silence Therapeutics only accepts job applications through our official careers site at Silence-Therapeutics.com/Careers.  If you’re contacted by someone claiming to represent Silence Therapeutics outside of these channels, please be cautious. Do not share personal or financial information unless you’re applying through our verified platforms.  If you’re unsure about a message or job offer, feel free to contact us at HR@Silence-Therapeutics.com to ensure it’s legitimate.

Section iconCompany Overview

Headquarters
72 Hammersmith Road London, England w14 8th United Kingdom
Phone number
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
SLN
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
1999
Employees
51-200

Section iconFunding & Financials

  • $120M

    Silence Therapeutics plc has raised a total of $120M of funding over 5 rounds. Their latest funding round was raised on Feb 05, 2024 in the amount of $120M.

  • $25M$50M

    Silence Therapeutics plc's revenue is estimated to be in the range of $25M$50M

Section iconFunding & Financials

  • $120M

    Silence Therapeutics plc has raised a total of $120M of funding over 5 rounds. Their latest funding round was raised on Feb 05, 2024 in the amount of $120M.

  • $25M$50M

    Silence Therapeutics plc's revenue is estimated to be in the range of $25M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.